Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2025-10-21 Capital/Financing Update
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시)
Capital/Financing Update Classification · 95% confidence The document is titled '증권 발행결과(자율공시)' which translates to 'Securities Issuance Result (Voluntary Disclosure)'. It details the issuance of a specific type of security: a private placement of bonds with warrants (신주인수권부사채). The document includes issuance amount, dates, and related disclosures. There is no financial statement or comprehensive report content, but rather an announcement of the results of a capital raising activity. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length is short and focused on issuance results, not a full report or regulatory filing. Therefore, the classification is CAP with high confidence.
2025-10-21 Korean
소송등의제기ㆍ신청(경영권분쟁소송) (대표이사 직무집행 정지 가처분)
Legal Proceedings Report Classification · 100% confidence The document is a legal proceeding update regarding a management dispute lawsuit involving the suspension of the CEO's duties. It includes details such as case name, parties involved, claims, court jurisdiction, and dates. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to legal actions and court filings. Therefore, the document fits the category of Legal Proceedings Report (LTR). The document length is short but contains substantive legal information, not just an announcement or certification.
2025-10-21 Korean
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 95% confidence The document is titled '주요사항보고서(유상증자결정)' which translates to 'Material Fact Report (Decision on Paid-in Capital Increase)'. It is addressed to the Financial Services Commission and Korea Exchange, indicating a regulatory filing. The content details the decision to issue new shares via a third-party allotment, including specifics on share types, issuance price, subscription details, and the purpose of funds raised. This is a formal announcement of a capital increase event, not a full financial report or earnings release. The document length is about 5307 characters, which is relatively short and focused on the capital raising event. Therefore, it fits the category of Capital/Financing Update (CAP).
2025-10-20 Korean
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Capital/Financing Update Classification · 95% confidence The document is titled '주요사항보고서(신주인수권부사채 발행결정)' which translates to 'Material Information Report (Decision to Issue Bonds with Warrants)'. It contains detailed information about the issuance of convertible bonds with warrants, including terms such as principal amount, interest rate, maturity date, early redemption options, conversion prices, and related financial details. The document is a regulatory disclosure about a financing activity involving issuance of bonds with warrants. It is not an annual or quarterly financial report, nor a management or board change announcement. It is not a voting result or legal proceeding. The document is a detailed announcement about capital raising through bond issuance with warrants, which fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed substantive information about the financing terms, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the best classification is CAP with high confidence.
2025-10-14 Korean
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure regarding the issuance of convertible bonds with warrants (신주인수권부사채 발행결정) by the company (주)애드바이오텍. It includes extensive information about the bond issuance terms, conditions for loss of benefit of term, early redemption rights, conversion price adjustments, and related financial and legal provisions. The document is addressed to regulatory bodies such as the Financial Services Commission and the Korea Exchange, indicating it is a regulatory disclosure. The content focuses on capital raising through bond issuance and related financing details. It is not an annual or quarterly report, audit report, or earnings release. It is not a simple announcement of a report publication but a substantive disclosure about financing activity. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (over 14,000 characters), and it contains detailed financial and contractual information about the bond issuance, supporting a high confidence in classification.
2025-10-14 Korean
[기재정정]주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is titled '주요사항보고서(유상증자결정)' which translates to 'Material Information Report (Decision on Paid-in Capital Increase)'. It details the correction of a previously submitted material report regarding a paid-in capital increase (유상증자). The content includes specifics about the issuance of new shares, types of shares, conversion rights, subscription details, pricing, and the purpose of the capital raise. It also references regulatory provisions related to securities issuance and disclosure. The document is a formal announcement of a financing event (capital increase) and its correction, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive details about the capital increase itself. Therefore, the document fits the category of Capital/Financing Update (CAP).
2025-10-14 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.